Gene · 2642
Papers2,157
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,157
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention. | Kidney Int Rep | 2026 | 41726005 | PubTator, text mining | PubMed |
| Bridging the Gap Between Static Histology and Dynamic Organ-on-a-Chip Models. | Pathophysiology | 2026 | 41718388 | PubTator, text mining | PubMed |
| Population Pharmacokinetic/Pharmacodynamic Modeling of Volagidemab, a Glucagon Receptor Antagonist, in Healthy Chinese and US Subjects Following Single Subcutaneous Administration. | Pharm Res | 2026 | 41714547 | PubTator, text mining | PubMed |
| Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders. | Diabetes Metab Syndr Obes | 2026 | 41710720 | PubTator, text mining | PubMed |
| GLP-1 Is Not Enough: Can Glucagon Fill the Energy Expenditure Gap? | Neuroendocrinology | 2026 | 41678436 | PubTator, text mining | PubMed |
| Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues. | Mol Metab | 2026 | 41654015 | PubTator, text mining | PubMed |
| Challenging the recessive paradigm of Mahvash disease: heterozygous phenotypes from a novel splice-site variant. | Arch Endocrinol Metab | 2026 | 41649336 | PubTator, text mining | PubMed |
| Sequence constraints predispose Class D GPCRs to follow an atypical activation mechanism. | bioRxiv | 2026 | 41648123 | PubTator, text mining | PubMed |
| Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. | Mol Metab | 2026 | 41638399 | PubTator, text mining | PubMed |
| Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. | Curr Obes Rep | 2026 | 41575482 | PubTator, text mining | PubMed |
| All roads lead to Rome: Emergence of Mechanistic Divergence Shapes Activation of Class B1 G-Protein Coupled Receptors. | bioRxiv | 2026 | 41542565 | PubTator, text mining | PubMed |
| Novel Compounds as Glucagon Receptor Agonists for Treating Type 2 Diabetes Mellitus and Obesity. | ACS Med Chem Lett | 2026 | 41531971 | PubTator, text mining | PubMed |
| Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP-1, GIP, and Glucagon Agonists. | J Pept Sci | 2026 | 41518129 | PubTator, text mining | PubMed |
| Specific Glucagon Assay System Using a Receptor-Derived Glucagon-Binding Peptide Probe. | Int J Mol Sci | 2026 | 41516388 | PubTator, text mining | PubMed |
| IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. | Pharmacol Res | 2026 | 41478576 | PubTator, text mining | PubMed |
| Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities. | Gut | 2026 | 41475978 | PubTator, text mining | PubMed |
| Mazdutide versus placebo in Chinese adults with type 2 diabetes. | Nature | 2026 | 41407859 | PubTator, text mining | PubMed |
| Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. | Contemp Clin Trials | 2026 | 41260459 | PubTator, text mining | PubMed |
| Advances in Incretin-Based Therapies for MAFLD: Mechanisms and Clinical Evidence. | Clin Pharmacol Ther | 2026 | 41243582 | PubTator, text mining | PubMed |
| Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. | Diabetes Obes Metab | 2026 | 41216778 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2642/papers?page=5